Using advanced genetic testing to manage drug-resistant tuberculosis
Official title: Targeted Sequencing to Enhance, Liberate, and Optimize Treatment of Drug-resistant Tuberculosis
Run by University of California, San Francisco · NCT05553236 · Data updated 2026-11-12
This study tests if advanced genetic testing can help doctors make better treatment choices for people with drug-resistant tuberculosis to improve their health outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Sex | All |
| Enrollment | 2500 (estimated) |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (Cape Town) |
| Status | Recruiting |
| Started | August 1, 2024 |
| Main results expected | January 2027 |
| Study ends | January 2027 |
| Registry record updated | January 26, 2026 |
| Trial ID | NCT05553236 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals diagnosed with active rifampin-resistant tuberculosis who are receiving care at participating facilities.
✕Probably not a fit
Patients who do not have active RR-TB or those who are unwilling to participate in the study may not benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial evaluates the effectiveness of a next-generation sequencing approach in managing rifampin-resistant tuberculosis (RR-TB) and improving patient outcomes. It employs a stepped-wedge, cluster randomized design to assess how this genetic testing strategy influences treatment decisions and health results. Participants include individuals diagnosed with active RR-TB at designated facilities, and the study aims to provide insights into the cost-effectiveness of this innovative management strategy.
Why it matters
Potential benefit: If successful, this approach could lead to more effective treatment strategies for patients with drug-resistant tuberculosis.
How similar studies have gone: Other studies utilizing next-generation sequencing for tuberculosis management have shown promising results, indicating potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Active RR-TB diagnosed at a study facility during the study period 2. Positive Mtb culture, smear, or specimen derivative (e.g., GenoLyse remnant, Xpert cartridge extract) Exclusion Criteria: 1. Patient expects to relocate/move residence outside of the study region 2. Patient does not agree to participate in the study In addition, participants later found to have isolates with rifamycin susceptibility on at least two additional tests (e.g., phenotypic DST, LPA, or sequencing) will be considered late exclusions.
Where it's running
-
South African National Health Laboratory Service
Cape Town, South Africa Recruiting
Study contacts
- Principal investigator: John Z Metcalfe, MD, PhD — University of California, San Francisco
- Study coordinator: John Z Metcalfe, MD, PhD
- Email: john.metcalfe@ucsf.edu
- Phone: +14152068314
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
eCardiacRehab: a home-based, patient-centered cardiac rehab program
This trial tests a hybrid home-based cardiac rehabilitation program to see if it reduces cardiovascular deaths and ED visits while improving quality of life for adults with CAD after PCI, compared with usual care.
-
Monitoring linezolid blood levels to reduce treatment interruptions in rifampin-resistant TB
This project will test whether checking linezolid blood levels and adjusting doses helps people with rifampin-resistant TB stay on treatment longer.
-
Comparing nurse-led and physician-led treatment for drug-resistant tuberculosis
This study is testing whether treatment for drug-resistant tuberculosis led by nurses in local clinics works as well as treatment by doctors in hospitals, to see if it can help patients get better care at a lower cost.
-
Evaluating inpatient versus outpatient treatment for chronic depression
This study is testing whether treating chronic depression in the hospital or at home works better and costs less for people with this condition.
-
Health-Enhancing Adapted Physical Activity Program
This study is testing a 16-week exercise program to see if it helps people with chronic diseases stick to physical activity and improve their health.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.